PL2582366T3 - Kombinacja farmaceutyczna do leczenia bólu - Google Patents

Kombinacja farmaceutyczna do leczenia bólu

Info

Publication number
PL2582366T3
PL2582366T3 PL11730199T PL11730199T PL2582366T3 PL 2582366 T3 PL2582366 T3 PL 2582366T3 PL 11730199 T PL11730199 T PL 11730199T PL 11730199 T PL11730199 T PL 11730199T PL 2582366 T3 PL2582366 T3 PL 2582366T3
Authority
PL
Poland
Prior art keywords
pain
treatment
pharmaceutical combination
pharmaceutical
combination
Prior art date
Application number
PL11730199T
Other languages
English (en)
Inventor
Klaus Schiene
Petra Bloms-Funke
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2582366(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL2582366T3 publication Critical patent/PL2582366T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11730199T 2010-06-15 2011-06-14 Kombinacja farmaceutyczna do leczenia bólu PL2582366T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15
EP11730199.4A EP2582366B1 (en) 2010-06-15 2011-06-14 Pharmaceutical combination for the treatment of pain
PCT/EP2011/002905 WO2011157391A1 (en) 2010-06-15 2011-06-14 Pharmaceutical combination for the treatment of pain

Publications (1)

Publication Number Publication Date
PL2582366T3 true PL2582366T3 (pl) 2016-04-29

Family

ID=42395008

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11730199T PL2582366T3 (pl) 2010-06-15 2011-06-14 Kombinacja farmaceutyczna do leczenia bólu

Country Status (29)

Country Link
US (3) US8846765B2 (pl)
EP (2) EP2992877A1 (pl)
JP (3) JP6133772B2 (pl)
KR (1) KR101831616B1 (pl)
CN (1) CN103108631B (pl)
AR (1) AR081931A1 (pl)
AU (2) AU2011267474B2 (pl)
BR (1) BR112012031836A2 (pl)
CA (1) CA2796774C (pl)
CL (1) CL2012002551A1 (pl)
CO (1) CO6602157A2 (pl)
CY (1) CY1117118T1 (pl)
DK (1) DK2582366T3 (pl)
EC (2) ECSP12012217A (pl)
ES (1) ES2560676T3 (pl)
HK (2) HK1184370A1 (pl)
HR (1) HRP20151327T1 (pl)
HU (1) HUE026619T2 (pl)
IL (1) IL221926A (pl)
MX (1) MX2012014482A (pl)
NZ (1) NZ602625A (pl)
PE (2) PE20160531A1 (pl)
PL (1) PL2582366T3 (pl)
PT (1) PT2582366E (pl)
RS (1) RS54439B1 (pl)
RU (2) RU2589692C2 (pl)
SI (1) SI2582366T1 (pl)
WO (1) WO2011157391A1 (pl)
ZA (1) ZA201208646B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX2014010939A (es) * 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
RS59687B1 (sr) * 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
EP3636251B1 (en) 2013-03-15 2022-01-19 Janssen Pharmaceutica NV Pharmaceutical composition of s-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
EP3139943A4 (en) * 2014-05-06 2018-07-18 Northwestern University Combinations of nmdar modulating compounds
MA40462A (fr) 2014-08-13 2017-06-21 Janssen Pharmaceutica Nv Méthode de traitement de la dépression
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CA3096671A1 (en) * 2018-04-12 2019-10-17 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
US20230117657A1 (en) 2019-03-05 2023-04-20 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
CN1309562A (zh) 1998-07-16 2001-08-22 纪念斯隆-凯特林癌症中心 包括一种阿片样物质镇痛剂和一种nmda拮抗剂的局部给药组合物
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
WO2004022002A2 (en) 2002-09-09 2004-03-18 Endo Pharmaceuticals Inc. Combined immediate release and extended release analgesic composition
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
EP2012763B1 (en) 2006-04-28 2011-03-23 Grünenthal GmbH Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
CN101431990B (zh) 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
AU2007256352A1 (en) * 2006-06-08 2007-12-13 Ucb Pharma Gmbh Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
MX2010005680A (es) * 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101641519B1 (ko) * 2008-09-05 2016-07-21 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
WO2012038813A1 (en) 2010-09-21 2012-03-29 Purdue Pharma L.P. Buprenorphine analogs
PL2826467T3 (pl) 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
CN107088226A (zh) 2011-03-04 2017-08-25 格吕伦塔尔有限公司 他喷他多的胃肠外给药
CA3120681A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Also Published As

Publication number Publication date
HK1215787A1 (zh) 2016-09-15
JP2013528629A (ja) 2013-07-11
AR081931A1 (es) 2012-10-31
ZA201208646B (en) 2013-09-25
PE20130243A1 (es) 2013-03-22
JP6133772B2 (ja) 2017-05-24
KR101831616B1 (ko) 2018-04-04
CY1117118T1 (el) 2017-04-05
WO2011157391A1 (en) 2011-12-22
ES2560676T3 (es) 2016-02-22
AU2016219643B2 (en) 2018-04-12
HK1184370A1 (zh) 2014-01-24
CA2796774A1 (en) 2011-12-22
EP2582366A1 (en) 2013-04-24
US20170333369A1 (en) 2017-11-23
PT2582366E (pt) 2016-01-26
HRP20151327T1 (hr) 2016-01-01
NZ602625A (en) 2014-03-28
EP2582366B1 (en) 2015-10-28
ECSP19047259A (es) 2019-07-31
KR20130111945A (ko) 2013-10-11
IL221926A (en) 2015-08-31
CN103108631B (zh) 2015-08-26
AU2011267474B2 (en) 2016-05-26
JP2017141277A (ja) 2017-08-17
SI2582366T1 (sl) 2016-02-29
CO6602157A2 (es) 2013-01-18
RU2016119041A (ru) 2017-11-20
AU2016219643A1 (en) 2016-09-15
CA2796774C (en) 2020-06-02
RS54439B1 (en) 2016-06-30
JP6197007B2 (ja) 2017-09-13
JP2015232015A (ja) 2015-12-24
BR112012031836A2 (pt) 2016-11-08
US10813890B2 (en) 2020-10-27
DK2582366T3 (en) 2015-12-07
RU2675261C2 (ru) 2018-12-18
HUE026619T2 (en) 2016-06-28
AU2011267474A1 (en) 2013-01-10
US20110306674A1 (en) 2011-12-15
ECSP12012217A (es) 2012-11-30
CL2012002551A1 (es) 2012-11-09
US8846765B2 (en) 2014-09-30
JP6423036B2 (ja) 2018-11-14
PE20160531A1 (es) 2016-06-05
MX2012014482A (es) 2013-02-21
RU2589692C2 (ru) 2016-07-10
US20140309311A1 (en) 2014-10-16
CN103108631A (zh) 2013-05-15
RU2013101515A (ru) 2014-07-20
EP2992877A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
HK1184370A1 (zh) 用於治療疼痛的藥物組合
ZA201300831B (en) Corticosteroids for the treatment of joint pain
EP2528603A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS
GB2479213B (en) Pharmaceutical formulations for the treatment of overactive bladder
EP2654745A4 (en) COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
HK1182015A1 (zh) 活性藥物化合物用於治療中樞神經系統病症的用途
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2776042A4 (en) DRUG POLYTHERAPY FOR THE TREATMENT OF SOLID TUMORS
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
ZA201301458B (en) Therapeutic agent for pain
EP2536436A4 (en) ANTIMIR-451 FOR THE TREATMENT OF POLYCYTHEMICS
IL235272B (en) Alfentanil composition for the treatment of acute pain
PL2608685T3 (pl) Urządzenie do obróbki tytoniu
PL2531124T3 (pl) Urządzenia do leczenia zmian skórnych
EP2548580A4 (en) PHARMACEUTICAL FOR PSEUDOTRAINING THERAPY
PL2456445T3 (pl) Środek do leczenia chorób skóry
PT2566579E (pt) Dispositivo médico para magnetoterapia
HK1202239A1 (en) Combination drug therapy for the treatment of solid tumors
GB201009194D0 (en) Treatment of pain
IL204097A0 (en) Medicine for the treatment of skin cancer
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
EP2531186A4 (en) TREATMENT OF HAIR DRESSES